Here, we hypothesized that (1) DNA-based signatures tracking breast cancer biological processes can be detected in ctDNA and provide clinically useful information and (2) DNA-signatures detected in plasma and tissue can help identify tumor subtypes within hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. Here, HR is linked to breast carcinoma.